Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)
- Conditions
- Relapsed or Refractory Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 27
- Registration Number
- NCT04666649
- Locations
- 🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2020-12-08
- Last Posted Date
- 2025-09-04
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 101
- Registration Number
- NCT04657081
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Stanford University, Palo Alto, California, United States
🇺🇸Yale University, New Haven, Connecticut, United States
ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN
- Conditions
- Myelodysplastic Syndrome (MDS)Acute Myeloid Leukemia (AML)Myeloproliferative Neoplasm (MDS/MPN)
- Interventions
- First Posted Date
- 2020-11-20
- Last Posted Date
- 2023-05-12
- Lead Sponsor
- Gwynn Long, M.D.
- Target Recruit Count
- 3
- Registration Number
- NCT04639024
- Locations
- 🇺🇸
Duke University Health System, Durham, North Carolina, United States
A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic/Myeloproliferative NeoplasmMyeloproliferative Neoplasm
- Interventions
- First Posted Date
- 2020-11-19
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT04637009
- Locations
- 🇺🇸
University of Alabama - Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸University of Southern California Keck School of Medicine, Los Angeles, California, United States
IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation
- Conditions
- Myeloid LeukemiaAllogeneic Stem Cell TransplantationMyelodysplastic Syndromes
- Interventions
- Drug: IFN-γ (interferon gamma-1b) injection
- First Posted Date
- 2020-11-13
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Sawa Ito, MD
- Target Recruit Count
- 8
- Registration Number
- NCT04628338
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- Conditions
- Acute Myeloid LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2020-10-30
- Last Posted Date
- 2025-08-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 153
- Registration Number
- NCT04609826
- Locations
- 🇫🇷
CHU de Nice Hopital de l Archet, Nice, France
🇫🇷Hopital Saint Louis, Paris, France
🇫🇷Centre Hospitalier Universitaire (CHU) de Bordeaux Hopital HautLeveque Centre Francois Magendie, Pessac, France
Phase 1 Study of Oral LY3410738 in Patients with Advanced Hematologic Malignancies with IDH1 or IDH2 Mutations.
- Conditions
- Advanced Hematologic Malignancies
- Interventions
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Eli Lilly & Co.
- Target Recruit Count
- 34
- Registration Number
- 2024-515149-41-00
- Locations
- 🇫🇷
Hospices Civils De Lyon, Pierre Benite, France
🇫🇷Hopital Saint Louis, Paris, France
Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)
- Conditions
- Relapsed Acute Myeloid Leukemia
- Interventions
- Procedure: Donor lymphocyte infusion
- First Posted Date
- 2020-10-12
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 11
- Registration Number
- NCT04582864
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Monocentric Phase 1 Study With Escalation of Doses of Tocilizumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients With Acute Myeloblastic Leukemia (AML)
- Conditions
- Acute Myeloid Leukemia (AML)
- First Posted Date
- 2020-09-14
- Last Posted Date
- 2023-04-28
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT04547062
- Locations
- 🇫🇷
CHU of Nantes, Nantes, France
A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML)
- First Posted Date
- 2020-08-12
- Last Posted Date
- 2022-05-05
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 14
- Registration Number
- NCT04509622
- Locations
- 🇯🇵
NHO Nagoya Medical Center /ID# 223671, Nagoya-shi, Aichi, Japan
🇯🇵Aichi Cancer Center Hospital /ID# 223134, Nagoya-shi, Aichi, Japan
🇯🇵University of Fukui Hospital /ID# 223133, Yoshida-gun, Fukui, Japan